Tonix Pharmaceuticals Holding Corp

NASDAQ:TNXP   3:59:50 PM EDT
0.22
-0.03 (-10.40%)
Products, Strategic Combinations

Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration with Kansas State University to Develop LNP-Free mRNA Vaccines

Published: 01/04/2022 12:16 GMT
Tonix Pharmaceuticals Holding Corp (TNXP) - Tonix Pharmaceuticals Announces Exclusive Option and Research Collaboration With Kansas State University to Develop Lnp-free Mrna Vaccines.
Tonix Pharmaceuticals - Znp Technology Expected to Improve Mrna Vaccine Temperature Stability for Storage and Transport.
Tonix Pharmaceuticals - New Zinc Nanoparticle (znp) Technology Replaces Lipid Nanoparticle (lnp) Technology Employed in Current Mrna Covid-19 Vaccines.
Tonix - K-state Will Advance Preclinical Development of New Znp Mrna Vaccine to Protect Against Covid-19 Based on Spike Protein From Sars-cov-2.